Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Amortization - IntangiblesConsolidated Net IncomeCost of RevenueDepreciation & Amortization - TotalEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyNet Income towards Common StockholdersOperating ExpensesOperating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax Rate
Others
Ratios

Vanda Pharmaceuticals (VNDA) Revenue (2016 - 2025)

Historic Revenue for Vanda Pharmaceuticals (VNDA) over the last 17 years, with Q4 2025 value amounting to $57.2 million.

  • Vanda Pharmaceuticals' Revenue rose 757.92% to $57.2 million in Q4 2025 from the same period last year, while for Dec 2025 it was $216.1 million, marking a year-over-year increase of 872.0%. This contributed to the annual value of $216.1 million for FY2025, which is 872.0% up from last year.
  • As of Q4 2025, Vanda Pharmaceuticals' Revenue stood at $57.2 million, which was up 757.92% from $56.3 million recorded in Q3 2025.
  • In the past 5 years, Vanda Pharmaceuticals' Revenue registered a high of $70.1 million during Q3 2021, and its lowest value of $38.8 million during Q3 2023.
  • Moreover, its 5-year median value for Revenue was $56.7 million (2025), whereas its average is $56.5 million.
  • Its Revenue has fluctuated over the past 5 years, first plummeted by 4057.53% in 2023, then surged by 2276.44% in 2024.
  • Over the past 5 years, Vanda Pharmaceuticals' Revenue (Quarter) stood at $68.0 million in 2021, then dropped by 5.2% to $64.5 million in 2022, then decreased by 29.79% to $45.3 million in 2023, then increased by 17.48% to $53.2 million in 2024, then rose by 7.58% to $57.2 million in 2025.
  • Its Revenue was $57.2 million in Q4 2025, compared to $56.3 million in Q3 2025 and $52.6 million in Q2 2025.